$1.34
1.52% day before yesterday
Nasdaq, Dec 24, 09:36 pm CET
ISIN
US19249H1032
Symbol
CHRS

Coherus BioSciences, Inc. Stock price

$1.34
+0.06 4.69% 1M
+0.57 74.55% 6M
-0.04 2.90% YTD
-0.13 8.84% 1Y
-5.11 79.22% 3Y
-16.01 92.28% 5Y
-21.63 94.17% 10Y
-11.27 89.37% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.02 1.52%
ISIN
US19249H1032
Symbol
CHRS
Industry

Key metrics

Basic
Market capitalization
$162.0m
Enterprise Value
$20.9m
Net debt
positive
Cash
$191.7m
Shares outstanding
116.2m
Valuation (TTM | estimate)
P/E
1.0 | negative
P/S
1.9 | 3.6
EV/Sales
0.3 | 0.5
EV/FCF
negative
P/B
1.9
Financial Health
Equity Ratio
-29.4%
Return on Equity
-21.6%
ROCE
-118.4%
ROIC
-370.9%
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$83.6m | $44.6m
EBITDA
$-166.7m | $-180.5m
EBIT
$-170.8m | $-173.2m
Net Income
$155.0m | $-173.1m
Free Cash Flow
$-90.2m
Growth (TTM | estimate)
Revenue
-72.5% | -83.3%
EBITDA
-36.2% | -94.4%
EBIT
-33.7% | -76.4%
Net Income
34,537.8% | -707.2%
Free Cash Flow
-45.4%
Margin (TTM | estimate)
Gross
47.8%
EBITDA
-199.5% | -404.5%
EBIT
-204.4%
Net
185.4% | -387.9%
Free Cash Flow
-107.9%
More
EPS
$1.3
FCF per Share
$-0.8
Short interest
25.7%
Employees
228
Rev per Employee
$1.2m
Show more

Is Coherus BioSciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Coherus BioSciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Coherus BioSciences, Inc. forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Coherus BioSciences, Inc. forecast:

Buy
82%
Hold
18%

Financial data from Coherus BioSciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
84 84
73% 73%
100%
- Direct Costs 44 44
74% 74%
52%
40 40
71% 71%
48%
- Selling and Administrative Expenses 112 112
33% 33%
134%
- Research and Development Expense 99 99
1% 1%
119%
-167 -167
36% 36%
-200%
- Depreciation and Amortization 4.06 4.06
24% 24%
5%
EBIT (Operating Income) EBIT -171 -171
34% 34%
-204%
Net Profit 155 155
34,538% 34,538%
185%

In millions USD.

Don't miss a Thing! We will send you all news about Coherus BioSciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Coherus BioSciences, Inc. Stock News

Positive
Seeking Alpha
3 days ago
Coherus Oncology maintains a 'Buy' rating, driven by a promising clinical pipeline and undervaluation relative to cash and equity holdings. CHRS's commercial growth is anchored by toripalimab sales in a niche U.S. indication, but profitability hinges on pipeline success. Key catalysts include mid-2026 data readouts for casdozokitug and CHS-114; no major Q1 2026 milestones are expected.
Neutral
GlobeNewsWire
18 days ago
-6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy - -6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy -
Neutral
Seeking Alpha
about 2 months ago
Coherus Oncology, Inc. ( CHRS ) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST Company Participants Dennis Lanfear - Chairman, President & CEO Theresa Lavallee - Chief Development Officer & Chairman of Scientific Advisory Board Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Divisio...
More Coherus BioSciences, Inc. News

Company Profile

Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Head office United States
CEO Denny Lanfear
Employees 228
Founded 2010
Website www.coherus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today